COURAGE THERAPEUTICS INC
Newton, MA · CIK 0002069873 · Biotech · Private
Small molecule therapeutics targeting MC4R and MC3R receptors for metabolic disorders
couragetx.com →- Grants
- $4.3M
- 7 awards
- Sector median: 1
- Raised
- $4.5M
- 1 Form D · May 2025
- 17 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 0 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss | $244,905 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Melanocortin-3 Receptor Peptide Antagonists for the Treatment of Obesity and Maintenance of Weight Loss | $244,905 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa | $250,538 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of Melanocortin-3 Receptor Peptide Agonists for the Treatment of Anorexia Nervosa | $250,538 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency | $806,879 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency | $1,669,553 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency | $862,674 | |
| Private capital raised | Form D · SEC | $4,510,963 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1870 | Jennerex, Inc. | — | $5.4M |
| 1871 | AKTTYVA THERAPEUTICS, INC. | — | — |
| 1872 | Oncolix, Inc. | — | $8.9M |
| 1873 | COURAGE THERAPEUTICS INC | — | $4.5M |
| 1874 | Factor Holdings LLC | — | $25K |
| 1875 | TearSolutions, Inc. | — | $36M |
| 1876 | Optimvia, LLC | — | $75K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Isaac BarchasDirector
- Roger ConeDirector
- Daniel HousmanDirector · Executive Officer
- Bruce LeutcherDirector
Patents
- MC4R Agonist Peptidesapplication
- MC3R Agonist Peptidesapplication
- Anorexia-sensitizing Agentsapplication
- MC3R Agonist Peptidesapplication
- MC3R Antagonist Or Partial Agonist Peptidesapplication
- MC3R Agonist Peptidesapplication
- Anorexia-sensitizing Agentsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.